Separate what is known from what is still being investigated
Cancer of unknown primary does not mean that clinicians know nothing. It means cancer has been confirmed but the original site has not been identified despite appropriate assessment.
More testing is not automatically better. A test is most useful when its result could change treatment, clarify the working diagnosis or help control symptoms. Ask the team to explain the point at which treatment can begin without finding the primary.
Create a working-diagnosis sheet
Update this after each review rather than carrying disconnected results.
- What has pathology confirmed about the cell type or likely family of cancers?
- Which scans, markers or examinations have been completed, and what did each add?
- What remains genuinely uncertain?
- Which further test is proposed and what decision could change because of it?
- What treatment aim is being discussed while investigations continue?
- Which symptoms need support now, regardless of whether the primary is found?
Questions for the MDT discussion
Ask the clinician to distinguish evidence from probability.
- What is the current working diagnosis and how confident is the team?
- What features of the pathology point towards or away from particular origins?
- Would finding the primary change the treatment being recommended?
- When will the team stop investigating and make a treatment decision?
- Could a specialist CUP team, pathology review or molecular test add something useful?
Asking for a plain summary
It is reasonable to ask the clinician to slow down.
“Could you give me three sentences: what we know, what we do not know and what decision happens next?”
Work with what is known while uncertainty remains
Cancer of unknown primary, often shortened to CUP, means cancer has been found away from its starting site but the original cancer cannot be identified. Care can still be based on the tissue, pattern of spread, symptoms and what matters to you.
The diagnosis is not a sign that nobody has looked properly. Very small primary tumours can be difficult to see, may have changed, or may no longer be detectable. Pathology, scans, blood tests and sometimes molecular tests are used to narrow the likely origin and identify features that could guide treatment. The team may use terms such as provisional CUP while investigations continue and confirmed CUP once reasonable testing has not found a primary.
More testing is not always more helpful. Each proposed test should have a clear question behind it: could the result change treatment, clarify prognosis, relieve a symptom or identify a highly treatable pattern? Tests can also carry burdens such as travel, preparation, biopsy risk and delay. It is reasonable to ask why the team recommends stopping investigations when further results are unlikely to alter care.
Treatment may be directed at the most likely cancer type, at a molecular feature, or at the pattern and symptoms of disease. Supportive and palliative care can be offered alongside anticancer treatment and does not mean that care has stopped. Because uncertainty is emotionally exhausting, ask for one named contact and a written summary of what is known, what remains uncertain and what the next review will decide.
A practical way through it
Use the parts that fit your situation and leave the rest.
- Ask which CUP term appliesFind out whether the team considers the diagnosis provisional or confirmed and which investigations are still expected to add useful information.
- Build a facts listWrite down the biopsy site, pathology description, areas seen on imaging and any features that point towards or away from a likely primary.
- Question each new testAsk what result it could produce, how that result would change care, and what burden or delay the test involves.
- Request the treatment rationaleAsk whether the proposed approach is based on likely origin, tumour features, symptoms, general health or a combination of these.
- Bring symptoms into the planDescribe pain, appetite, sleep, mobility, breathlessness and emotional strain so supportive treatment is not postponed while the diagnosis is refined.
- Choose a communication anchorAgree which clinician or specialist nurse will coordinate questions and tell other professionals about the working diagnosis and current plan.
What this can look like
When another scan is not recommended
Ruth feels that stopping tests means the team is giving up, while the clinician says another scan is very unlikely to identify the primary or change the proposed treatment.
A useful response
Ask the clinician to explain what has already been excluded and what uncertainty remains.
Ask what decision the extra scan would need to change to justify its burden or delay.
Request a second clinical opinion if substantial uncertainty about the plan remains after that explanation.
What CUP means
- Pathology, location and molecular features can still provide useful clues.
- Tests may include examination, blood tests, biopsy, scans and selected molecular tests.
When investigation stops
- Ask what each further test might add to treatment or care.
- Investigation may stop when it is unlikely to change treatment or improve care.
Planning care
- Options depend on cell type, likely origin, sites involved, general health and personal wishes.
- Treatment may include drug treatment, radiotherapy, surgery or symptom-focused care.
A manageable next step
What you could do now
- Ask what the pathology already tells the team.
- Ask whether another test would change the plan.
- Write down the aim of each treatment option discussed.
Checked sources
Read the original guidance
We summarise carefully and link to the source so you can check the full, most current information. Sources were checked 9 September 2026.